Samsung Biologics Co.,Ltd. (KRX:207940)

South Korea flag South Korea · Delayed Price · Currency is KRW
1,778,000
+12,000 (0.68%)
At close: Feb 27, 2026
-0.99%
Market Cap 82.31T
Revenue (ttm) 4.56T
Net Income (ttm) 1.78T
Shares Out 46.29M
EPS (ttm) 26,628.00
PE Ratio 73.80
Forward PE 47.44
Dividend n/a
Ex-Dividend Date n/a
Volume 97,725
Average Volume 54,855
Open 1,760,000
Previous Close 1,766,000
Day's Range 1,741,000 - 1,778,000
52-Week Range 1,509,860 - 1,987,000
Beta 0.21
RSI 55.53
Earnings Date Apr 29, 2026

About Samsung Biologics

Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. The company operates through Contract Development and Manufacturing Organization (CDMO), and Biopharmaceutical Development and Commercialization segments. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, fini... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2011
Employees 4,770
Stock Exchange Korea Stock Exchange
Ticker Symbol 207940
Full Company Profile

Financial Performance

In 2025, Samsung Biologics's revenue was 4.56 trillion, an increase of 0.21% compared to the previous year's 4.55 trillion. Earnings were 1.78 trillion, an increase of 64.68%.

Financial Statements

News

Samsung BioLogics Co Ltd (XKRX:207940) Q4 2026 Earnings Report Preview: What To Look For

Samsung BioLogics Co Ltd (XKRX:207940) Q4 2026 Earnings Report Preview: What To Look For

5 weeks ago - GuruFocus

Samsung Biologics Expands U.S. Presence with $280M Acquisition

Samsung Biologics Expands U.S. Presence with $280M Acquisition

2 months ago - GuruFocus

Samsung Biologics To Acquire GSK's Rockville Facility For US$280 Mln

(RTTNews) - Samsung Biologics (207940.KS) announced that its wholly owned U.S. subsidiary, Samsung Biologics America, will acquire 100% of Human Genome Sciences from GSK (GSK, GSK.L) for US$280 millio...

2 months ago - Nasdaq

Samsung Biologics to Acquire Human Genome Sciences from GSK

Samsung Biologics to Acquire Human Genome Sciences from GSK

2 months ago - GuruFocus

Samsung BioLogics Co Ltd (XKRX:207940) Q3 2025: Everything You Need To Know Ahead Of Earnings

Samsung BioLogics Co Ltd (XKRX:207940) Q3 2025: Everything You Need To Know Ahead Of Earnings

4 months ago - GuruFocus

Korean Stock Market Declines Amid Trade Uncertainty; Samsung Biologics (SSNLF) Drops

Korean Stock Market Declines Amid Trade Uncertainty; Samsung Biologics (SSNLF) Drops

5 months ago - GuruFocus

Asian drug market stocks slides: Trump’s 100% pharmaceutical tariffs shake market; broader impact on Japan likely minimal

Asian drug stocks faced a downturn. This followed US President Trump's tariff threat on imported pharmaceuticals. South Korean and Japanese drugmakers experienced declines. Samsung Biologics and Sumit...

5 months ago - The Times of India